Evaluating the effectiveness of anti-tuberculosis treatment by detecting Mycobacterium tuberculosis 85B messenger RNA expression in sputum.


Journal

Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 07 02 2020
revised: 08 05 2020
accepted: 19 05 2020
pubmed: 4 7 2020
medline: 28 4 2021
entrez: 4 7 2020
Statut: ppublish

Résumé

The antigen 85 complex (85B) is secreted in large quantities from growing mycobacteria and the presence of bacterial mRNA is an indicator of cell viability. The quantitative detection of 85B mRNA expression levels can be used to assess the success of anti-tuberculosis treatment outcomes to detect viable mycobacteria cells. Therefore, we evaluated the levels of 85B mRNA of Mycobacterium tuberculosis strains in patients with pulmonary tuberculosis. Thirty patients with primary tuberculosis were included in this study. The sputum specimens of patients were collected on days 0, 15, and 30 days and were cultured and evaluated by 85B mRNA-based RT-qPCR. Overall, 23 of the studied tuberculosis strains were susceptible to the primary anti-tuberculosis antibiotics used in this study, 7 were resistant. By the 30th day of treatment, 85B mRNA was detected in only one of the susceptible strains, but in all 7 of the resistant strains, though the relative gene expression varied between the strains. This difference between the susceptible and resistant strains at day 30 was statistically significant (p < 0.05). 85B mRNA expression levels could be used to follow up on primary tuberculosis cases. 85B mRNA seems to be a good diagnostic marker for monitoring anti-tuberculosis treatment outcomes.

Sections du résumé

BACKGROUND BACKGROUND
The antigen 85 complex (85B) is secreted in large quantities from growing mycobacteria and the presence of bacterial mRNA is an indicator of cell viability. The quantitative detection of 85B mRNA expression levels can be used to assess the success of anti-tuberculosis treatment outcomes to detect viable mycobacteria cells. Therefore, we evaluated the levels of 85B mRNA of Mycobacterium tuberculosis strains in patients with pulmonary tuberculosis.
METHODS METHODS
Thirty patients with primary tuberculosis were included in this study. The sputum specimens of patients were collected on days 0, 15, and 30 days and were cultured and evaluated by 85B mRNA-based RT-qPCR.
RESULTS RESULTS
Overall, 23 of the studied tuberculosis strains were susceptible to the primary anti-tuberculosis antibiotics used in this study, 7 were resistant. By the 30th day of treatment, 85B mRNA was detected in only one of the susceptible strains, but in all 7 of the resistant strains, though the relative gene expression varied between the strains. This difference between the susceptible and resistant strains at day 30 was statistically significant (p < 0.05).
CONCLUSION CONCLUSIONS
85B mRNA expression levels could be used to follow up on primary tuberculosis cases. 85B mRNA seems to be a good diagnostic marker for monitoring anti-tuberculosis treatment outcomes.

Identifiants

pubmed: 32616395
pii: S1876-0341(20)30482-2
doi: 10.1016/j.jiph.2020.05.016
pii:
doi:

Substances chimiques

Antitubercular Agents 0
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1490-1494

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Ersan Atahan (E)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Pulmonary Diseases, Istanbul, Turkey.

Suat Saribas (S)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Microbiology, Istanbul, Turkey. Electronic address: suatsaribas@gmail.com.

Mehmet Demirci (M)

Beykent University Medical Faculty, Department of Medical Microbiology, Istanbul, Turkey.

Aylin Babalık (A)

Clinic of Chest Diseases, University of Health Sciences, Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital, Istanbul, Turkey.

Seher Akkus (S)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Microbiology, Istanbul, Turkey.

Ahmet Balıkcı (A)

Clinic of Chest Diseases, University of Health Sciences, Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital, Istanbul, Turkey.

Dilek Satana (D)

Istanbul University, Istanbul Faculty of Medicine, Department of Medical Microbiology, Istanbul, Turkey.

Tevhide Ziver (T)

Eastern Mediterranean University, Faculty of Health Sciences, Nutrition and Dietetic Department, Famagusta, Cyprus.

Harika Oyku Dinc (HO)

Okan University, Medical Faculty, Department of Medical Microbiology, Istanbul, Turkey.

Melike Keskin (M)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Microbiology, Istanbul, Turkey.

Dogukan Ozbey (D)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Microbiology, Istanbul, Turkey.

Banu Tufan Kocak (BT)

T.C. Health Ministry Erenkoy Mental Health and Neurology Training and Research Hospital, Istanbul, Turkey.

Nesrin Gareayaghi (N)

Istanbul Sisli Hamidiye Etfal Training and Research Hospital, Blood Center, University of Health Sciences, Istanbul, Turkey.

Sahra Kirmusaoglu (S)

T.C. Haliç University, Faculty of Arts & Sciences, Department of Molecular Biology and Genetics, Istanbul, Turkey.

Hrisi Bahar Tokman (HB)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Microbiology, Istanbul, Turkey.

Bekir Kocazeybek (B)

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Microbiology, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH